-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA Approves Bristol Myers Squibb's Breyanzi for Relapsed or Refractory Marginal Zone Lymphoma

路透·12/05/2025 01:15:22

登录查看新闻详情